FDA Advises Medication Error Risk Assessment Early In Development
This article was originally published in The Tan Sheet
FDA’s draft guidance on safety considerations for product and container design to minimize medication errors calls for assessments in “real world” settings early in the development process. Relying solely on clinical trials is inadequate for a number of factors the agency and sponsors need to know about a new drug product, the draft says.
You may also be interested in...
FDA issues guidance on splitting tablets
FDA releases drug patch guidance
Some drug firms may need to alter their product packaging and labeling to comply with FDA's guidance on dosing device labeling for liquid OTCs